SCHEMBL12895625

SCHEMBL12895625

CCNc1cnc(F)c(C)c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 1/20 0.37
▸ ADRA2A P08913 2/20 0.36
▸ ADRA2B P18089 2/20 0.36
▸ ADRA2C P18825 2/20 0.36
▸ BACE1 P56817 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ RECQL P46063 1/20 0.32
▸ RRM2 P31350 1/20 0.31
▸ ALOX5 P09917 1/20 0.31
▸ RXRA P19793 1/20 0.30
▸ GRIN1 Q05586 1/20 0.30
▸ GRIN2B Q13224 1/20 0.30
▸ EGFR P00533 1/20 0.30
▸ HRH3 Q9Y5N1 1/20 0.30
▸ F10 P00742 1/20 0.30
▸ LCK P06239 1/20 0.30
▸ BTK Q06187 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14007418 0.78 KDM4E (0.33) BACE1CYP3A4ALOX5EGFRBTK
SCHEMBL9347591 0.77 CHEK1 (0.37) CHEK1ADRA2AADRA2BADRA2CEGFR
SCHEMBL12883375 0.77 HDAC3 (0.31) ALOX5
SCHEMBL31584353 0.76 KMT2A (0.47) TSHR
SCHEMBL25231546 0.76 BACE1 (0.33) BACE1CYP3A4ALOX5
SCHEMBL14320151 0.72 ALDH1A1 (0.33) ALOX5
SCHEMBL28723884 0.72 KCNQ3 (0.40) BACE1
SCHEMBL25097479 0.70 ADRA2A (0.42) CHEK1ADRA2AADRA2BADRA2CTSHR
SCHEMBL9970964 0.69 NOS3 (0.35) RXRAGRIN1GRIN2B
SCHEMBL4570831 0.69 RECQL (0.40) ADRA2AADRA2BADRA2CCYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110039838-A1 PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-02-17 — — US disclosed
US-7846931-B2 Pyrrolotriazine compounds as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-12-07 — — US disclosed
US-20090048244-A1 PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-02-19 — — US disclosed
US-7297695-B2 Pyrrolotriazine compounds as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039838-A1 PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS ERBB2, ERBB4, ERBB3 CHEK1 472/4885ADRA2A 3771/4885ADRA2B 3534/4885
US-20090048244-A1 PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS ERBB2, ERBB4, ERBB3 CHEK1 472/4885ADRA2A 3771/4885ADRA2B 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback